[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351977-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351977-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recent-advancements-and-limitations-of-intestinal-organoids-for-clinical-applications","Recent advancements and limitations of intestinal organoids for clinical applications","","Colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide, with incidence rising among younger populations despite advances in molecular characterization. Converting discoveries into effective therapies is hindered by limitations of conventional preclinical models, including 2D systems and patient-derived xenografts, which cannot fully reproduce CRC tissue complexity and heterogeneity. Intestinal organoids, generated from adult or pluripotent stem cells, provide a 3D model that preserves structural, genetic, and functional features, supporting long-term growth and more physiological studies of CRC initiation, progression, and drug resistance. Their value is further expanded through CRISPR/Cas9 editing, high-throughput drug screening, and multi-omics integration for personalized medicine, though challenges such as culture variability, limited protocol standardization, and incomplete tumor microenvironment representation, especially immune and stromal components, remain. This review synthesizes key organoid technologies, identifies knowledge gaps, and highlights strategies to advance clinical translation and precision oncology outcomes for CRC patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recent-advancements-and-limitations-of-intestinal-organoids-for-clinical-applications/351977/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recent-advancements-and-limitations-of-intestinal-organoids-for-clinical-applications/351977.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are conventional preclinical models insufficient for colorectal cancer research?","Question",{"text":63,"@type":64},"Conventional models such as 2D systems and patient-derived xenografts do not recapitulate CRC tissue complexity and heterogeneity, creating a gap between laboratory findings and clinical performance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What advantages do intestinal organoids offer for studying colorectal cancer?",{"text":68,"@type":64},"Intestinal organoids mimic structural, genetic, and functional characteristics of native intestinal tissue in a 3D culture environment, preserve patient-specific genomic features, and enable long-term growth for studying CRC initiation, progression, and drug resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"Which emerging technologies enhance the utility of organoids in personalized medicine and drug discovery?",{"text":72,"@type":64},"Integration with CRISPR/Cas9 genome editing, high-throughput drug screening, and multi-omics technologies improves organoid usefulness in personalized medicine and drug discovery.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351977,1790187203,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Prog. Biomed. Eng. 8 (2026) 032010 [https://doi.org/10.1088/2516-1091/ae8107](https://doi.org/10.1088/2516-1091/ae8107)  \nProgress in Biomedical Engineering  \n\n| |\n| --- |\n|  |\n| OPEN ACCESS\u003Cbr>RECEIVED\u003Cbr>22 January 2026\u003Cbr>REVISED\u003Cbr>26 May 2026\u003Cbr>ACCEPTED FOR PUBLICATION 23 June 2026\u003Cbr>PUBLISHED\u003Cbr>13 July 2026 |\n\nOriginal content from this work may be used under the terms of the  \nCreative Commons Attribution 4 .0 licence.  \nAny further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.  \nTOPICAL REVIEW  \nRecent advancements and limitations of intestinal organoids for clinical applications  \nMd Zahirul Islam Khan1,2􀁂, Somrita Roy1, Soumya Nair1, Asma Pinkey3, Taslim Al-Hilal4, Helen Ka-Wai Law5 and Sourav Roy1,2, ∗  \n1 Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, United States of America  \n2 The Border Biomedical Research Center, University of Texas at El Paso, El Paso, TX 79968, United States of America  \n3 Department of Environmental Science and Engineering, University of Texas at El Paso, El Paso, TX 79968, United States of America  \n4 Departments of Molecular Pharmaceutics and Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, United States of America  \n5 Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region of China, People’s Republic of China  \n∗ Author to whom any correspondence should be addressed.  \nE-mail: [sroy1@utep.edu](sroy1@utep.edu)  \nKeywords: organoid, colorectal cancer, 3D culture, application, limitation, drug development  \nAbstract  \nColorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, and there has been a concerning rise in its incidence among younger populations. Although there have been significant advances in molecular characterization, translating research findings into effective therapeutic strategies for CRC management remains suboptimal. This challenge is largely attributed to the limitations of conventional preclinical models, such as two-dimensional or patient-derived tumor xenograft (PDX), which fail to recapitulate the complexity and heterogeneity ofCRC tissues. Intestinal organoids, derived from adult or pluripotent stem cells, have emerged as transformative tools to address the current limitations by mimicking the structural, genetic, and functional characteristics of native intestinal tissue in a three-dimensional culture environment. These organoids preserve patient-specific genomic features, allowing long-term growth, and serve as amore physiologically relevant model for studying CRC initiation, progression and drug resistance mechanisms. Furthermore, the integration of organoids with CRISPR/Cas9 genome editing, highthroughput drug screening, and multi-omics technologies has greatly enhanced their utility in personalized medicine and drug discovery. However, several unsolved challenges remain with the organoid model, such as culturing variability, a lack of protocol standardization, and an incomplete representation of the tumor microenvironment, particularly immune and stromal cells. This review offers a critical and comprehensive overview of intestinal organoid technologies in CRC research, identifies major knowledge gaps, and highlights emerging strategies to enhance their clinical application. The study aims to provide future directions that could significantly enhance precision oncology and ultimately improve therapeutic outcomes for CRC patients.  \n1. Background  \nColorectal cancer (CRC) develops from the abnormal growth of polyps in the colon or rectum, which can eventually become cancerous. Globally, CRC is the third most commonly diagnosed cancer, accounting for approximately 10% of all cancer cases. It is also the second leading cause of cancer-related deaths [1] . Recent epidemiological trends reveal a notable decline i","cbCaikisURWgjwM7","https://ap.wps.com/l/cbCaikisURWgjwM7","pdf",894835,"English","# Background\n## Colorectal cancer epidemiology and age-related trends\n## Molecular heterogeneity and signaling pathways\n## Gap between preclinical models and clinical outcomes","[{\"question\":\"Why are conventional preclinical models insufficient for colorectal cancer research?\",\"answer\":\"Conventional models such as 2D systems and patient-derived xenografts do not recapitulate CRC tissue complexity and heterogeneity, creating a gap between laboratory findings and clinical performance.\"},{\"question\":\"What advantages do intestinal organoids offer for studying colorectal cancer?\",\"answer\":\"Intestinal organoids mimic structural, genetic, and functional characteristics of native intestinal tissue in a 3D culture environment, preserve patient-specific genomic features, and enable long-term growth for studying CRC initiation, progression, and drug resistance.\"},{\"question\":\"Which emerging technologies enhance the utility of organoids in personalized medicine and drug discovery?\",\"answer\":\"Integration with CRISPR/Cas9 genome editing, high-throughput drug screening, and multi-omics technologies improves organoid usefulness in personalized medicine and drug discovery.\"}]","Recent advancements and limitations of intestinal organoids for clinical applications | PDF",1790096651,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ceb6a0a1f5e3e27c46435d08ae1fc03.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0a36359ebb33e0deb2cce9e4ae13d29.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f22b05502cd8bd85774a2479b39c130d.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/277fba077b5ae8df4d815598949be383.webp",980,1385]